- Live Conference Call and Webcast at
4:30 PM ET -
PALO
ALTO, Calif., July 28,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals,
Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical
company focused on the development of innovative therapies for
hepatitis delta virus (HDV) and other serious diseases, today
announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022
financial results and provide a business update.
The live and replayed webcast of the call will be available
through the company's website at www.eigerbio.com. To participate
in the live call by phone, please register in advance at
https://register.vevent.com/register/BIfd526d893fcb47fc96359096e28232bb
to receive the dial-in number and unique passcode to access the
call. The webcast will be archived and available for replay for at
least 90 days after the event.
About Eiger
Eiger is a commercial-stage
biopharmaceutical company focused on the development of innovative
therapies for hepatitis delta virus (HDV) and other serious rare
diseases. The Eiger HDV platform includes two first-in-class
therapies in Phase 3 that target critical host processes involved
in viral replication. All five Eiger rare disease programs have
been granted FDA breakthrough therapy designation.
For additional information about Eiger and its
clinical programs, please
visit www.eigerbio.com.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2022-financial-results-and-business-update-on-thursday-august-4-301594940.html
SOURCE Eiger BioPharmaceuticals, Inc.